Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi (ONCSM) Fair Value & Analysis
Healthcare · TR · Market cap 6.0B TRY
Fair value as of: Aug 1, 2026
From 24 valuation models · updated today
Share price +0.7% over the past month.
What matters now
- The price sits above even our optimistic bull case (58.11 TRY). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (24.80 TRY to 58.11 TRY) leaves room in how you read the outcome.
Price vs Fair Value (12 months)
12‑month range 95.30 TRY – 380.00 TRY · fair‑value band 24.80 TRY – 58.11 TRY · the 252.75 TRY price screens above the 46.48 TRY fair value. As of Aug 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi (ONCSM) currently trades at 252.75 TRY, while our model-based Fair Value estimate is 46.48 TRY, implying the stock looks roughly 81.6% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi generated revenue of 729M TRY at a net margin of 6.4%. Revenue grew 8.9% year over year. It earns a return on equity of 12.3%. Net debt stands at 41.4M TRY. Fundamentals as of Aug 1, 2026
Our scenario range runs from 24.80 TRY (bear case) to 58.11 TRY (bull case); at 252.75 TRY, the current price sits above that range. The share trades about 35% below its 52-week high and 168% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at -82%, ONCSM screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi manufactures and sells chemotherapy drug preparation kits and equipment in Turkey.
Full company description
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi manufactures and sells chemotherapy drug preparation kits and equipment in Turkey. The company offers OncoCare Monolitik, an automated chemotherapy drug preparation device; OncoCare Plus, a chemotherapy drug guide; OncoWaste and M-Waste, a hazardous waste sealing system, chemotherapy drugs, cephalosporins, penicillins, infectious waste and toxic laboratory waste; OncoCare Set, a chemotherapy preparation and administration consumables; and Oncocare Infusion Pump. It also provides Oncosem components, such as pinch clamps, roller clamps, 3/4 way connectors, vial adapters, drip chambers, hydrophobic caps, male and rotating luer locks, spikes, taxol filters, check valves, and covers. The company was incorporated in 2008 and is headquartered in Ankara, Turkey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi reported revenue of 709M TRY in FY2025 versus 128M TRY in FY2021, a compound +53.4%/yr. Reported net income was 50.4M TRY in FY2025, compounding −8.4%/yr from FY2021.
Is ONCSM fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $87.83 | $78.63 | -10% |
| Stryker Corporation SYK | $304.69 | $186.28 | -39% |
| Medtronic plc 2M6 | €70.24 | €46.70 | -34% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $39.91 | $48.29 | +21% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
| STERIS plc S1TE34 | R$52.14 | R$39.46 | -24% |
| Zimmer Biomet Holdings Z1BH34 | R$111.66 | R$17.42 | -84% |
| Shanghai United Imaging Healthcare Co 688271 | ¥112.98 | ¥56.52 | -50% |
Compare Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi (ONCSM) overvalued or undervalued?
What is the fair value of ONCSM?
What is the quality score of ONCSM?
What is the revenue of Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi (ONCSM)?
What is the net profit margin of ONCSM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.